The price-to-earnings ratio for Genmab ADR (NASDAQ: GMAB) is above average at 12.34x. The 36-month beta value for GMAB is also noteworthy at 1.01. There are mixed opinions on the stock, with 3 analysts rating it as a “buy,” 2 rating it as “overweight,” 5 rating it as “hold,” and 0 rating it as “sell.”
The public float for GMAB is 635.39M, and at present, short sellers hold a 0.25% of that float. The average trading volume of GMAB on February 18, 2025 was 1.35M shares.
GMAB) stock’s latest price update
Genmab ADR (NASDAQ: GMAB)’s stock price has plunge by 1.48relation to previous closing price of 21.30. Nevertheless, the company has seen a 15.65% surge in its stock price over the last five trading sessions. seekingalpha.com reported 2025-02-18 that Genmab reported strong Q4 2024 results, with $897.4 million in revenue, beating expectations and showing 29% Y/Y growth, driven by Darzalex royalties. 2025 revenue guidance was slightly ahead of consensus and expense guidance was surprisingly low, indicating only 7% growth, and enhancing the company’s financial outlook. J&J’s decision on GEN3014 is pending; I expect J&J to opt out, but remain bullish on Genmab’s product portfolio, pipeline, and growth prospects.
GMAB’s Market Performance
GMAB’s stock has risen by 15.65% in the past week, with a monthly rise of 1.86% and a quarterly drop of -0.21%. The volatility ratio for the week is 2.96% while the volatility levels for the last 30 days are 2.32% for Genmab ADR The simple moving average for the last 20 days is 7.50% for GMAB stock, with a simple moving average of -11.81% for the last 200 days.
Analysts’ Opinion of GMAB
Many brokerage firms have already submitted their reports for GMAB stocks, with Leerink Partners repeating the rating for GMAB by listing it as a “Outperform.” The predicted price for GMAB in the upcoming period, according to Leerink Partners is $27 based on the research report published on February 13, 2025 of the current year 2025.
Morgan Stanley gave a rating of “Equal-Weight” to GMAB, setting the target price at $31 in the report published on September 04th of the previous year.
GMAB Trading at 4.39% from the 50-Day Moving Average
After a stumble in the market that brought GMAB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -32.20% of loss for the given period.
Volatility was left at 2.32%, however, over the last 30 days, the volatility rate increased by 2.96%, as shares surge +3.65% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -0.65% lower at present.
During the last 5 trading sessions, GMAB rose by +15.36%, which changed the moving average for the period of 200-days by -22.14% in comparison to the 20-day moving average, which settled at $20.10. In addition, Genmab ADR saw 3.57% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for GMAB
Current profitability levels for the company are sitting at:
- 0.31 for the present operating margin
- 0.96 for the gross margin
The net margin for Genmab ADR stands at 0.23. The total capital return value is set at 0.18. Equity return is now at value 23.16, with 19.54 for asset returns.
Based on Genmab ADR (GMAB), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at 6.82. The debt to equity ratio resting at 0.03. The interest coverage ratio of the stock is 124.26.
Currently, EBITDA for the company is 5.56 billion with net debt to EBITDA at -0.81. When we switch over and look at the enterprise to sales, we see a ratio of 4.65. The receivables turnover for the company is 3.13for trailing twelve months and the total asset turnover is 0.5. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.25.
Conclusion
In summary, Genmab ADR (GMAB) has had a mixed performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
